ProFibrix B.V. reached the one-yard line with its Fibrocaps based on €40 million in equity funding, but rather than amass commercial scale to compete in the surgical products market, the company accepted a takeout bid from The Medicines Co. (NASDAQ:MDCO).

In June, Medicines Co. paid $10 million for an exclusive option to acquire ProFibrix for another $90 million in cash plus up to $140 million in milestones.